Sanofi has said goodbye to Lexicon, but after years of failing to keep up with rivals, there is scope for the French drug maker to make more drastic cuts to its diabetes…
Blaming manufacturing delays and competitive pressure, Autolus asks investors to reset expectations.
A strong second quarter pushed Novartis’s stock up 5% this morning, but Kymriah continues to look weak, and the jury is still out on Zolgensma.
Yet another project brought in through business development fails, exposing Sumitomo’s limited pipeline.
The ripples of Molmed’s pivotal study failure could stretch beyond the company’s Zalmoxis product.
Turning Point is heading into a highly competitive lung cancer niche with its lead project, which still has much to prove.
The German group’s decision to switch focus to innate immunity had been on the cards since a deal with Roche last August.
The mere possibility of Guardant horning in on colorectal cancer has spooked Exact’s investors.
By taking out Abide Therapeutics, Lundbeck has bought one of very few clinical-stage Tourette’s syndrome candidates.